CardioMech AS, a Trondheim, Norway-based medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology, raised $13M in funding.
The round, which brought the total amount to $42M, saw participation from from existing and new investors, including a non-disclosed strategic investor.
The company intends to use the funds to expand operations and its R&D sector.
Led by Rick Nehm, President and CEO, and Jacob Bergsland, MD, Founder, CardioMech is developing its transcatheter mitral valve chordal repair technology. Its device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible.
FinSMEs
02/01/2024